OTC · LVCLY
Living Cell Technologies Limited
Healthcare · Biotechnology
$0.03
Up+$0.01 (+24.39%)
Updated Sep 20, 2026, 11:53 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.39M
- P/E ratio
- -11.55
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 244
- Avg. volume
- 908
Price performance
LVCLY price history
1M range · 0 trading sessions · Daily adjusted prices
LVCLY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest LVCLY news
The latest Smart Investors Daily articles mentioning LVCLY.
Stock researchCompany · Overview
LVCLY research
Overview
Company profile and research snapshot.
Company profile
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
